Drug Profile
AMG 228
Alternative Names: AMG228Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Amgen
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action TNFRSF18 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Australia (IV)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Belgium (IV)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in France (IV)